Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 13/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498846 | 0.85 | PGR (0.43) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL5501394 | 0.76 | ACHE (0.40) | ALDH1A1KDM4EMAPTHSD17B10LMNA | |
| SCHEMBL5504997 | 0.73 | ELANE (0.37) | ALDH1A1KDM4EMAPTHSD17B10LMNA | |
| SCHEMBL12647196 | 0.72 | PGR (0.43) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL8024917 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL5508770 | 0.70 | ALDH1A1 (0.38) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL6650129 | 0.67 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL10840500 | 0.62 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL5504578 | 0.62 | CES1 (0.46) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL26649009 | 0.61 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | ALDH1A1 4580/4885KDM4E 4073/4885HPGD 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.